首页 > 最新文献

Gastrointestinal cancer research : GCR最新文献

英文 中文
Alternate dosing of cetuximab for patients with metastatic colorectal cancer. 西妥昔单抗在转移性结直肠癌患者中的替代剂量。
Joleen M Hubbard, Steven R Alberts

Background: Many chemotherapeutic regimens used to treat colorectal cancer (CRC), including 5-fluorouracil plus leucovorin in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX), are administered on an every-other-week (q2w) dosing schedule. Chemotherapy in combination with a monoclonal antibody (mAb) directed toward the epidermal growth factor receptor (EGFR) has emerged as an effective treatment option. There are currently 2 anti-EGFR mAbs approved by the United States Food and Drug Administration: cetuximab and panitumumab. Mutations of KRAS, a downstream protein in the EGFR pathway, predict resistance to EGFR mAbs. Thus, cetuximab and panitumumab are indicated for patients without a KRAS mutation (KRAS wild-type). Whereas panitumumab is approved on a q2w dosing schedule, cetuximab is approved as a weekly dose. However, only cetuximab is approved with FOLFIRI for frontline metastatic CRC, whereas panitumumab is approved for third-line. Because concomitant therapies are often administered q2w, the weekly dosing of cetuximab results in additional medical office visits.

Design: Several studies have assessed the safety and efficacy of cetuximab q2w. For this review, a comprehensive literature search of studies evaluating cetuximab q2w dosing was conducted. Safety and efficacy results of these trials and retrospective analyses were summarized and reviewed.

Results: In general, results with cetuximab q2w were comparable to those obtained with the weekly regimen.

Conclusion: These data suggest that for patients for whom weekly treatment with cetuximab presents a substantial burden to their quality of life, q2w dosing of cetuximab is a viable treatment option with a benefit:risk profile similar to that of the weekly regimen.

背景:许多用于治疗结直肠癌(CRC)的化疗方案,包括5-氟尿嘧啶加亚叶酸钙联合伊立替康(FOLFIRI)或奥沙利铂(FOLFOX),每隔一周(q2w)给药。化疗联合针对表皮生长因子受体(EGFR)的单克隆抗体(mAb)已成为一种有效的治疗选择。目前,美国食品和药物管理局批准了两种抗egfr单克隆抗体:西妥昔单抗和帕尼单抗。KRAS (EGFR通路中的下游蛋白)的突变可以预测对EGFR单克隆抗体的耐药性。因此,西妥昔单抗和帕尼单抗适用于没有KRAS突变(KRAS野生型)的患者。帕尼单抗被批准为每季度给药一次,而西妥昔单抗被批准为每周给药一次。然而,只有西妥昔单抗和FOLFIRI被批准用于一线转移性CRC,而帕尼单抗被批准用于三线。由于伴随治疗通常每两周进行一次,每周给药西妥昔单抗会导致额外的医疗办公室就诊。设计:几项研究评估了西妥昔单抗q2w的安全性和有效性。在本综述中,我们对评价西妥昔单抗q2w剂量的研究进行了全面的文献检索。对这些试验的安全性和有效性结果以及回顾性分析进行了总结和回顾。结果:总的来说,西妥昔单抗q2w治疗的结果与每周治疗的结果相当。结论:这些数据表明,对于每周接受西妥昔单抗治疗对其生活质量造成重大负担的患者,每2周给药西妥昔单抗是一种可行的治疗选择,其获益:风险概况与每周方案相似。
{"title":"Alternate dosing of cetuximab for patients with metastatic colorectal cancer.","authors":"Joleen M Hubbard,&nbsp;Steven R Alberts","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Many chemotherapeutic regimens used to treat colorectal cancer (CRC), including 5-fluorouracil plus leucovorin in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX), are administered on an every-other-week (q2w) dosing schedule. Chemotherapy in combination with a monoclonal antibody (mAb) directed toward the epidermal growth factor receptor (EGFR) has emerged as an effective treatment option. There are currently 2 anti-EGFR mAbs approved by the United States Food and Drug Administration: cetuximab and panitumumab. Mutations of KRAS, a downstream protein in the EGFR pathway, predict resistance to EGFR mAbs. Thus, cetuximab and panitumumab are indicated for patients without a KRAS mutation (KRAS wild-type). Whereas panitumumab is approved on a q2w dosing schedule, cetuximab is approved as a weekly dose. However, only cetuximab is approved with FOLFIRI for frontline metastatic CRC, whereas panitumumab is approved for third-line. Because concomitant therapies are often administered q2w, the weekly dosing of cetuximab results in additional medical office visits.</p><p><strong>Design: </strong>Several studies have assessed the safety and efficacy of cetuximab q2w. For this review, a comprehensive literature search of studies evaluating cetuximab q2w dosing was conducted. Safety and efficacy results of these trials and retrospective analyses were summarized and reviewed.</p><p><strong>Results: </strong>In general, results with cetuximab q2w were comparable to those obtained with the weekly regimen.</p><p><strong>Conclusion: </strong>These data suggest that for patients for whom weekly treatment with cetuximab presents a substantial burden to their quality of life, q2w dosing of cetuximab is a viable treatment option with a benefit:risk profile similar to that of the weekly regimen.</p>","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674463/pdf/gcr47.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic appendiceal carcinoma diagnosed in an asymptomatic patient with incidental thyroid mass on routine examination. 转移性阑尾癌的诊断无症状的病人附带甲状腺肿块的常规检查。
Sharan Prakash Sharma, Lewis M Attas
{"title":"Metastatic appendiceal carcinoma diagnosed in an asymptomatic patient with incidental thyroid mass on routine examination.","authors":"Sharan Prakash Sharma,&nbsp;Lewis M Attas","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674466/pdf/gcr64.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutaneous metastasis of pancreatic adenocarcinoma as a first clinical manifestation: a case report and review of the literature. 胰腺腺癌皮肤转移为第一临床表现:1例报告及文献复习。
Kassem Bdeiri, Francois G Kamar
{"title":"Cutaneous metastasis of pancreatic adenocarcinoma as a first clinical manifestation: a case report and review of the literature.","authors":"Kassem Bdeiri,&nbsp;Francois G Kamar","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674465/pdf/gcr61.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upcoming articles. 即将到来的文章。
{"title":"Upcoming articles.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674469/pdf/gcr72.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. 调强放射治疗与三维适形放射治疗肛管鳞状细胞癌的比较。
Michael D Chuong, Jessica M Freilich, Sarah E Hoffe, William Fulp, Jill M Weber, Khaldoun Almhanna, William Dinwoodie, Nikhil Rao, Kenneth L Meredith, Ravi Shridhar

Purpose: We compared our institutional experience using 3D conformal radiation therapy (3DCRT) vs. IMRT (intensity-modulated radiation therapy) for anal cancer.

Methods: We performed a single-institution retrospective review of all patients with squamous cell carcinoma anal cancer treated from September 2000 through September 2011, using definitive chemoradiation with curative intent.

Results: This study included 89 consecutive patients (37 3DCRT, 52 IMRT). Median follow-up for all patients, IMRT patients alone, and CRT patients alone was 26.5 months (range, 3.5-133.6), 20 months (range, 3.5-125.5), and 61.9 months (range, 7.6-133.6), respectively. Three-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and colostomy-free survival (CFS) were 91.1%, 82.3%, 90.8%, and 91.3% in the IMRT cohort and 86.1%, 72.5%, 91.9%, and 93.7% in the 3DCRT group (all P > .1). More patients in the 3DCRT group required a treatment break (11 vs. 4; P = .006), although the difference in median treatment break duration was not significant (12.2 vs. 8.0 days; P = .35). Survival did not differ based on whether a treatment break was needed (all P > .1). Acute grade ≥3 nonhematologic toxicity was decreased in the IMRT cohort (21.1 vs. 59.5%; P < .0001). Acute grade ≥3 skin toxicity was worse in the 3DCRT group (P < .0001), whereas an improvement in late grade ≥3 gastrointestinal (GI) toxicity was observed in the IMRT patients (P = .012).

Conclusions: This study is the largest thus far to compare 3DCRT and IMRT for definitive treatment of anal cancer. Although long-term outcomes did not significantly differ based on RT technique, a marked decrease in adverse effects and the need for a treatment break was achieved with IMRT.

目的:我们比较了我们的机构使用三维适形放射治疗(3DCRT)和IMRT(调强放射治疗)治疗肛门癌的经验。方法:我们对2000年9月至2011年9月期间接受治疗的所有鳞状细胞癌肛门癌患者进行了单机构回顾性研究,使用了具有治愈目的的明确放化疗。结果:本研究纳入89例连续患者(3DCRT 37例,IMRT 52例)。所有患者、单独IMRT患者和单独CRT患者的中位随访时间分别为26.5个月(范围3.5-133.6)、20个月(范围3.5-125.5)和61.9个月(范围7.6-133.6)。IMRT组3年总生存率(OS)、无进展生存率(PFS)、局部区域对照(LRC)和无结肠造口生存率(CFS)分别为91.1%、82.3%、90.8%和91.3%,3DCRT组为86.1%、72.5%、91.9%和93.7%(均P > 0.1)。3DCRT组更多患者需要治疗间隙(11 vs. 4;P = 0.006),但中位治疗中断时间差异不显著(12.2天vs 8.0天;P = .35)。生存率没有因是否需要中断治疗而差异(均P > 1)。急性≥3级非血液学毒性在IMRT队列中降低(21.1 vs. 59.5%;P < 0.0001)。3DCRT组急性≥3级皮肤毒性加重(P < 0.0001),而IMRT组晚期≥3级胃肠道(GI)毒性改善(P = 0.012)。结论:本研究是迄今为止最大规模的比较3DCRT和IMRT对肛门癌最终治疗的研究。尽管放疗技术的长期结果没有显著差异,但IMRT显著减少了不良反应,并且需要中断治疗。
{"title":"Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.","authors":"Michael D Chuong,&nbsp;Jessica M Freilich,&nbsp;Sarah E Hoffe,&nbsp;William Fulp,&nbsp;Jill M Weber,&nbsp;Khaldoun Almhanna,&nbsp;William Dinwoodie,&nbsp;Nikhil Rao,&nbsp;Kenneth L Meredith,&nbsp;Ravi Shridhar","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>We compared our institutional experience using 3D conformal radiation therapy (3DCRT) vs. IMRT (intensity-modulated radiation therapy) for anal cancer.</p><p><strong>Methods: </strong>We performed a single-institution retrospective review of all patients with squamous cell carcinoma anal cancer treated from September 2000 through September 2011, using definitive chemoradiation with curative intent.</p><p><strong>Results: </strong>This study included 89 consecutive patients (37 3DCRT, 52 IMRT). Median follow-up for all patients, IMRT patients alone, and CRT patients alone was 26.5 months (range, 3.5-133.6), 20 months (range, 3.5-125.5), and 61.9 months (range, 7.6-133.6), respectively. Three-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and colostomy-free survival (CFS) were 91.1%, 82.3%, 90.8%, and 91.3% in the IMRT cohort and 86.1%, 72.5%, 91.9%, and 93.7% in the 3DCRT group (all P > .1). More patients in the 3DCRT group required a treatment break (11 vs. 4; P = .006), although the difference in median treatment break duration was not significant (12.2 vs. 8.0 days; P = .35). Survival did not differ based on whether a treatment break was needed (all P > .1). Acute grade ≥3 nonhematologic toxicity was decreased in the IMRT cohort (21.1 vs. 59.5%; P < .0001). Acute grade ≥3 skin toxicity was worse in the 3DCRT group (P < .0001), whereas an improvement in late grade ≥3 gastrointestinal (GI) toxicity was observed in the IMRT patients (P = .012).</p><p><strong>Conclusions: </strong>This study is the largest thus far to compare 3DCRT and IMRT for definitive treatment of anal cancer. Although long-term outcomes did not significantly differ based on RT technique, a marked decrease in adverse effects and the need for a treatment break was achieved with IMRT.</p>","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674462/pdf/gcr39.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tenth Annual ISGIO Meeting. ISGIO第十届年会。
David H Ilson
{"title":"Tenth Annual ISGIO Meeting.","authors":"David H Ilson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674461/pdf/gcr37.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. 诊断为胰腺癌和骨髓增生异常综合征患者的处理。
Elizabeth Won, Kenneth H Yu, Ali Shamseddine, Leonard Saltz, Deborah Mukherjee, Ali Haydar, Ashwaq El-Olayan, Sally Temraz, Mohamed Naghy, Dorothy Makanjoula, Eileen M O'Reilly, Ghassan K Abou-Alfa
{"title":"Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome.","authors":"Elizabeth Won,&nbsp;Kenneth H Yu,&nbsp;Ali Shamseddine,&nbsp;Leonard Saltz,&nbsp;Deborah Mukherjee,&nbsp;Ali Haydar,&nbsp;Ashwaq El-Olayan,&nbsp;Sally Temraz,&nbsp;Mohamed Naghy,&nbsp;Dorothy Makanjoula,&nbsp;Eileen M O'Reilly,&nbsp;Ghassan K Abou-Alfa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674464/pdf/gcr56.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes of adenosquamous carcinoma of the pancreas. 胰腺腺鳞癌的特点和预后。
Pub Date : 2013-02-01 DOI: 10.1200/JCO.2013.31.4_SUPPL.311
C. Simone, Tania Zuluaga Toro, E. Chan, Michael M. Feely, J. Trevino, T. George
BACKGROUNDAdenosquamous carcinoma of the pancreas (ASCAP) is a rare histologic type of pancreatic carcinoma that constitutes 1% to 4% of all pancreatic exocrine malignancies. It has a clinical presentation similar to that of adenocarcinoma of the pancreas (ACP), but may have a worse overall prognosis, with most patients surviving for less than 2 years.METHODSThis was an institutional, retrospective, cohort analysis of 237 patients who underwent resection of pancreatic cancer with curative intent.RESULTSOf the 237 cases examined, we identified 7 (2.9%) with histologically confirmed ASCAP. Demographics, comorbidities, risk factors, presenting symptoms, survival data, tumor characteristics, and types of treatment for each patient were included in the analysis. Risk factors for development of ASCAP were not conclusive. Although human papilloma virus (HPV) has been implicated in other squamous cell cancers, in our cohort, its involvement in ASCAP was 0%. Presurgical fine-needle aspiration failed to identify the invasive squamous cell component in all cases. In this cohort analysis, overall survival ranged from 3 to 25 months, with 2 patients surviving more than 20 months after surgical resection. With a median follow-up of 2.9 years, our data demonstrate a trend to worse median overall survival for ASCAP than for ACP (8.2 vs. 20.4 months; P = .23), with a limited number of long-term survivors.CONCLUSIONSAlthough recommended, adjuvant treatment was inconsistently provided for patients in this ASCAP cohort. Published data show variability in overall survival, but our findings support that surgical resection is one of the few options for control of this rare, poorly understood pancreatic malignancy. Further research is necessary to define risk factors and adjuvant and neoadjuvant treatments, to help improve patient outcomes.
背景:胰腺腺鳞癌(ASCAP)是一种罕见的胰腺组织学类型,占所有胰腺外分泌恶性肿瘤的1%至4%。它的临床表现与胰腺腺癌(ACP)相似,但总体预后可能更差,大多数患者存活时间不到2年。方法:对237例以治愈为目的行胰腺癌切除术的患者进行制度性、回顾性、队列分析。结果在237例病例中,我们发现7例(2.9%)有组织学证实的ASCAP。每位患者的人口统计学、合并症、危险因素、表现症状、生存数据、肿瘤特征和治疗类型均纳入分析。发展ASCAP的危险因素尚无定论。虽然人类乳头状瘤病毒(HPV)与其他鳞状细胞癌有关,但在我们的队列中,其与ASCAP的关系为0%。术前细针抽吸未能在所有病例中发现浸润性鳞状细胞成分。在本队列分析中,总生存期从3到25个月不等,其中2例患者在手术切除后存活超过20个月。中位随访时间为2.9年,我们的数据显示ASCAP患者的中位总生存期比ACP患者更差(8.2个月对20.4个月;P = .23),长期幸存者数量有限。结论:虽然推荐了辅助治疗,但ASCAP队列患者的辅助治疗并不一致。已发表的数据显示总体生存率存在差异,但我们的研究结果支持手术切除是控制这种罕见的,知之甚少的胰腺恶性肿瘤的少数选择之一。进一步的研究是必要的,以确定危险因素和辅助和新辅助治疗,以帮助改善患者的预后。
{"title":"Characteristics and outcomes of adenosquamous carcinoma of the pancreas.","authors":"C. Simone, Tania Zuluaga Toro, E. Chan, Michael M. Feely, J. Trevino, T. George","doi":"10.1200/JCO.2013.31.4_SUPPL.311","DOIUrl":"https://doi.org/10.1200/JCO.2013.31.4_SUPPL.311","url":null,"abstract":"BACKGROUND\u0000Adenosquamous carcinoma of the pancreas (ASCAP) is a rare histologic type of pancreatic carcinoma that constitutes 1% to 4% of all pancreatic exocrine malignancies. It has a clinical presentation similar to that of adenocarcinoma of the pancreas (ACP), but may have a worse overall prognosis, with most patients surviving for less than 2 years.\u0000\u0000\u0000METHODS\u0000This was an institutional, retrospective, cohort analysis of 237 patients who underwent resection of pancreatic cancer with curative intent.\u0000\u0000\u0000RESULTS\u0000Of the 237 cases examined, we identified 7 (2.9%) with histologically confirmed ASCAP. Demographics, comorbidities, risk factors, presenting symptoms, survival data, tumor characteristics, and types of treatment for each patient were included in the analysis. Risk factors for development of ASCAP were not conclusive. Although human papilloma virus (HPV) has been implicated in other squamous cell cancers, in our cohort, its involvement in ASCAP was 0%. Presurgical fine-needle aspiration failed to identify the invasive squamous cell component in all cases. In this cohort analysis, overall survival ranged from 3 to 25 months, with 2 patients surviving more than 20 months after surgical resection. With a median follow-up of 2.9 years, our data demonstrate a trend to worse median overall survival for ASCAP than for ACP (8.2 vs. 20.4 months; P = .23), with a limited number of long-term survivors.\u0000\u0000\u0000CONCLUSIONS\u0000Although recommended, adjuvant treatment was inconsistently provided for patients in this ASCAP cohort. Published data show variability in overall survival, but our findings support that surgical resection is one of the few options for control of this rare, poorly understood pancreatic malignancy. Further research is necessary to define risk factors and adjuvant and neoadjuvant treatments, to help improve patient outcomes.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81343206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 47
A young woman with liver cancer. 一个患肝癌的年轻女子。
Celina S Ang, Richard K Do, Ali Shamseddine, Eileen M O'Reilly, Ali Haydar, Ashwaq Al-Olayan, Walid Faraj, Fouad Boulos, Mohamed Naghy, Dorothy Makanjoula, Hassan Farran, Hassan Sibai, David Wehbe, David P Kelsen, Ghassan K Abou-Alfa
{"title":"A young woman with liver cancer.","authors":"Celina S Ang,&nbsp;Richard K Do,&nbsp;Ali Shamseddine,&nbsp;Eileen M O'Reilly,&nbsp;Ali Haydar,&nbsp;Ashwaq Al-Olayan,&nbsp;Walid Faraj,&nbsp;Fouad Boulos,&nbsp;Mohamed Naghy,&nbsp;Dorothy Makanjoula,&nbsp;Hassan Farran,&nbsp;Hassan Sibai,&nbsp;David Wehbe,&nbsp;David P Kelsen,&nbsp;Ghassan K Abou-Alfa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597934/pdf/gcr17.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31316205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CME Post-Test. 芝加哥商品交易所测试后。
Pub Date : 2013-01-01 DOI: 10.1097/01720610-200709000-00005
{"title":"CME Post-Test.","authors":"","doi":"10.1097/01720610-200709000-00005","DOIUrl":"https://doi.org/10.1097/01720610-200709000-00005","url":null,"abstract":"","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72797726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gastrointestinal cancer research : GCR
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1